• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Lil­ly meets sales ex­pec­ta­tions, but No­vo gains on PBM win

Last week
Pharma

Ex­clu­sive: Ex-Cal­i­co sci­en­tist launch­es State­ly Bio with new way to study cells

Last week
Financing
AI

Am­i­cus grabs Dimer­ix’s rare kid­ney dis­ease drug for $30M up­front

Last week
Deals
Pharma

Mod­er­na ex­pands ef­fort to rein in costs in an ‘un­cer­tain en­vi­ron­ment’

Last week
R&D
Pharma

Teladoc buys vir­tu­al ther­a­py start­up Up­Lift for $30M

Last week
Deals
Health Tech

BeiGene scores a win from US Patent Of­fice in spat over Brukin­sa

Last week
Pharma
Law

Ex­its con­tin­ue at FDA, as more staff in drug of­fice fol­low fired col­leagues out the door

Last week
People
FDA+

Re­gen­eron los­es bid to fend off DOJ fight over Eylea Medicare pay­ments

Last week
Pharma
Law

Sci­en­tists alarmed about fu­ture of can­cer re­search; TIG­IT, CAR-NK and more from #AACR25

Last week
R&D

The End­points Slack in­ter­view: Arc In­sti­tute's Patrick Hsu on in­vest­ing, AI and new ways of re­search

Last week
People
AI

Im­mu­nic’s stock falls on mul­ti­ple scle­ro­sis da­ta; En­tra­da’s lay­offs

Last week
News Briefing

FDA ap­proves J&J's rare dis­ease drug that's ex­pect­ed to com­pete with ar­genx and UCB

Last week
Pharma
FDA+

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

Last week
Deals
Pharma

GSK's sup­ply chain 're­set' af­ter Ha­le­on spin­off to ease tar­iff im­pact, CEO says

Last week
Pharma
Manufacturing

Bridge­Bio’s At­tru­by out­per­forms sales ex­pec­ta­tions, shares rise

Last week
Pharma

Ex­clu­sive: No­ma Ther­a­py rais­es $4M for vir­tu­al ke­t­a­mine-as­sist­ed ther­a­py

Last week
Financing
Health Tech

Ar­tios drug ex­ploits ‘repli­ca­tion stress’ in can­cer, shrink­ing sub­set of tu­mors in ear­ly study

Last week
Startups
R&D

Pfiz­er CEO Bourla sug­gests phar­ma tar­iffs will fo­cus on US ad­ver­saries, not al­lies

Last week
China
Pharma

Join us at 12 p.m. ET: How phar­ma is re­act­ing to ‘Lib­er­a­tion Day’

Last week
Editor's note
Pharma

In­side De­vot­ed Health’s 2024 fi­nan­cials

Last week
Health Tech

Mer­ck plans to bring Keytru­da pro­duc­tion to the US with $1B bi­o­log­ics fac­to­ry

Last week
Manufacturing

FDA ap­proves Abeona’s skin dis­ease cell ther­a­py

Last week
Pharma
Cell/Gene Tx

FDA won't re­or­ga­nize med­ical prod­uct cen­ters, Makary says in in­ter­view: 'I re­ject­ed that pro­pos­al'

Last week
FDA+

Ab­b­Vie’s Rin­voq is ap­proved in gi­ant cell ar­teri­tis; Rel­ma­da shares blad­der can­cer da­ta

Last week
News Briefing
First page Previous page 2345678 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times